Literature DB >> 2148668

Increase in serum concentrations of IgG2 and IgG4 by selenium supplementation in children with Down's syndrome.

G Annerén1, C G Magnusson, S L Nordvall.   

Abstract

In a previous study on children with Down's syndrome a reduced rate of infections was reported by their parents after the children had received six months' treatment with selenium supplements. In the present study the concentrations of the four IgG subclasses were measured in 29 of these children in samples of serum obtained before and immediately after the period of supplementation and one year after it had finished. Selenium had a significant augmentative effect on the serum concentrations of IgG2 and IgG4, but not of IgG1 and IgG3. This effect was not related to age, as among children over the age of 6 years the serum concentrations of IgG2 and IgG4 had decreased significantly one year after the treatment had been stopped. This study suggests that selenium has an immunoregulatory effect, which might be of importance in both basic research and clinical practice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2148668      PMCID: PMC1793096          DOI: 10.1136/adc.65.12.1353

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  10 in total

Review 1.  The immune system and susceptibility to infections in Down's syndrome.

Authors:  S Levin
Journal:  Prog Clin Biol Res       Date:  1987

2.  Development of serum IgG subclass levels in children.

Authors:  S I Lee; D C Heiner; D Wara
Journal:  Monogr Allergy       Date:  1986

3.  Virus-specific immunoglobulin G subclasses in herpes simplex and varicella-zoster virus infections.

Authors:  V A Sundqvist; A Linde; B Wahren
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

4.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens.

Authors:  G R Siber; P H Schur; A C Aisenberg; S A Weitzman; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

5.  The quantification of human IgG subclasses in reference preparations.

Authors:  F Klein; F Skvaril; R Vermeeren; A Vlug; W J Duimel
Journal:  Clin Chim Acta       Date:  1985-08-15       Impact factor: 3.786

6.  Increased plasma and erythrocyte selenium concentrations but decreased erythrocyte glutathione peroxidase activity after selenium supplementation in children with Down syndrome.

Authors:  G Annerén; M Gebre-Medhin; K H Gustavson
Journal:  Acta Paediatr Scand       Date:  1989-11

Review 7.  Selenium and immune responses.

Authors:  L Kiremidjian-Schumacher; G Stotzky
Journal:  Environ Res       Date:  1987-04       Impact factor: 6.498

8.  Selenium and immune functions in humans.

Authors:  H Arvilommi; K Poikonen; I Jokinen; O Muukkonen; L Räsänen; J Foreman; J K Huttunen
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

9.  Trace element alterations in infectious diseases.

Authors:  U Srinivas; J H Braconier; B Jeppsson; M Abdulla; B Akesson; P A Ockerman
Journal:  Scand J Clin Lab Invest       Date:  1988-10       Impact factor: 1.713

10.  IgG subclass deficiency in patients with Down's syndrome and aberrant hepatitis B vaccine response.

Authors:  M A Avanzini; T Söderström; M Wahl; A Plebani; G R Burgio; L A Hanson
Journal:  Scand J Immunol       Date:  1988-10       Impact factor: 3.487

  10 in total
  3 in total

1.  Abnormal serum IgG subclass pattern in children with Down's syndrome.

Authors:  G Annerén; C G Magnusson; G Lilja; S L Nordvall
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

2.  Changed serum trace element profile in Down's syndrome.

Authors:  J Kadrabová; A Madáric; M Sustrová; E Ginter
Journal:  Biol Trace Elem Res       Date:  1996-09       Impact factor: 3.738

3.  Cytokine responses of human blood monocytes stimulated with Igs.

Authors:  J L Foreback; D G Remick; E Crockett-Torabi; P A Ward
Journal:  Inflammation       Date:  1997-10       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.